Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Sugarloaf Wealth Management LLC

Sugarloaf Wealth Management LLC grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 88.5% during the second quarter, HoldingsChannel.com reports. The fund owned 856 shares of the medical research company’s stock after purchasing an additional 402 shares during the quarter. Sugarloaf Wealth Management LLC’s holdings in Charles River Laboratories International were worth $180,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in CRL. Venturi Wealth Management LLC acquired a new position in shares of Charles River Laboratories International in the 1st quarter valued at about $25,000. Desjardins Global Asset Management Inc. acquired a new position in shares of Charles River Laboratories International in the 1st quarter valued at about $30,000. Tsfg LLC boosted its holdings in shares of Charles River Laboratories International by 49.1% in the 2nd quarter. Tsfg LLC now owns 158 shares of the medical research company’s stock valued at $33,000 after buying an additional 52 shares during the period. HighMark Wealth Management LLC acquired a new position in shares of Charles River Laboratories International in the 1st quarter valued at about $45,000. Finally, Covestor Ltd boosted its holdings in shares of Charles River Laboratories International by 100.0% in the 1st quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock valued at $49,000 after buying an additional 87 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling

In other Charles River Laboratories International news, Director Richard F. Wallman bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average cost of $198.79 per share, for a total transaction of $198,790.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $198,790. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CAO Michael Gunnar Knell sold 1,471 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $216.54, for a total transaction of $318,530.34. Following the sale, the chief accounting officer now owns 9,940 shares in the company, valued at $2,152,407.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard F. Wallman purchased 1,000 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were purchased at an average price of $198.79 per share, for a total transaction of $198,790.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at $198,790. The disclosure for this purchase can be found here. Insiders have sold 7,934 shares of company stock worth $1,722,048 in the last ninety days. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $0.98 during midday trading on Tuesday, reaching $209.59. The company’s stock had a trading volume of 286,358 shares, compared to its average volume of 517,398. The company has a current ratio of 1.49, a quick ratio of 1.21 and a debt-to-equity ratio of 0.82. The company has a 50 day moving average price of $206.21 and a 200 day moving average price of $202.53. Charles River Laboratories International, Inc. has a one year low of $181.22 and a one year high of $262.00. The company has a market cap of $10.75 billion, a price-to-earnings ratio of 22.34, a price-to-earnings-growth ratio of 1.86 and a beta of 1.33.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 9th. The medical research company reported $2.69 EPS for the quarter, topping analysts’ consensus estimates of $2.63 by $0.06. Charles River Laboratories International had a net margin of 11.58% and a return on equity of 18.99%. The business had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the previous year, the firm earned $2.77 EPS. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CRL shares. Bank of America boosted their target price on shares of Charles River Laboratories International from $235.00 to $245.00 and gave the company a “buy” rating in a research note on Thursday, August 10th. TD Cowen started coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 13th. They set a “market perform” rating and a $212.00 target price for the company. JPMorgan Chase & Co. boosted their target price on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Citigroup lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and reduced their target price for the company from $260.00 to $225.00 in a research note on Monday, July 10th. Five research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $244.55.

About Charles River Laboratories International

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).